Experienced in DICER1 Syndrome

Dr. Kristopher S. Lybarger

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Midwest Oncology Associates LLC
2316 E Meyer Blvd, 
Kansas City, MO 
Accepting New Patients
Offers Telehealth
Experienced in DICER1 Syndrome
Midwest Oncology Associates LLC
2316 E Meyer Blvd, 
Kansas City, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kristopher Lybarger is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Kansas City, Missouri. Dr. Lybarger is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Lump in the Abdomen, Endometrial Cancer, Vulvar Cancer, Hysterectomy, and Hernia Surgery. Dr. Lybarger is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MI
Hospital Affiliations
Cass Regional Medical Center
Centerpoint Medical Center
Western Missouri Medical Center
Research Medical Center
Belton Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MIDWEST ONCOLOGY ASSOCIATES LLC
2316 E Meyer Blvd, Kansas City, MO 64132
Other Locations
MIDWEST ONCOLOGY ASSOCIATES LLC
2000 Se Blue Pkwy, Suite 240, Lees Summit, MO 64063
MIDWEST ONCOLOGY ASSOCIATES LLC
10600 Quivira Rd, Suite 110, Overland Park, KS 66215
MIDWEST ONCOLOGY ASSOCIATES LLC
3889 S Jackson Dr, Independence, MO 64057

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Review of Evidence Supporting the Arista™ Absorbable Powder Hemostat.
Review of Evidence Supporting the Arista™ Absorbable Powder Hemostat.
Journal: Medical devices (Auckland, N.Z.)
Published: November 22, 2023
Similar Doctors
Experienced in DICER1 Syndrome
Dr. Blair R. Smith
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in DICER1 Syndrome
Dr. Blair R. Smith
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Health Physicians

2301 Holmes St, 
Kansas City, MO 
 (5.3 miles away)
816-404-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Blair Smith is a Gynecologic Oncologist and an Oncologist in Kansas City, Missouri. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Cervical Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Ovarian Cancer, and Hysterectomy. Dr. Smith is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Anis Toumeh
Oncology
Experienced in DICER1 Syndrome
Dr. Anis Toumeh
Oncology

Midwest Oncology Associates LLC

12140 Nall Ave, Suite 200, 
Overland Park, KS 
 (8.5 miles away)
913-498-7409
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anis Toumeh is an Oncologist in Overland Park, Kansas. Dr. Toumeh is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), and Pleuropulmonary Blastoma. Dr. Toumeh is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Raonak Ekram
Oncology | Hematology
Experienced in DICER1 Syndrome
Dr. Raonak Ekram
Oncology | Hematology

Saint Lukes Physician Group Inc

12330 Metcalf Ave, 
Overland Park, KS 
 (9.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raonak Ekram is an Oncologist and a Hematologist in Overland Park, Kansas. Dr. Ekram is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Ekram is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lybarger's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 56 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile